Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs

INTRODUCTION: To evaluate the comparative efficacy and safety of subcutaneous sarilumab 200 mg monotherapy administered every 2 weeks (q2w) versus other monotherapies of biologic, targeted and conventional synthetic disease-modifying antirheumatic drugs (bDMARDs, tsDMARDs, csDMARDs) at recommended d...

Descripción completa

Detalles Bibliográficos
Autores principales: Choy, Ernest, Freemantle, Nick, Proudfoot, Clare, Chen, Chieh-I, Pollissard, Laurence, Kuznik, Andreas, van Hoogstraten, Hubert, Mangan, Erin, Carita, Paulo, Huynh, Thi-Minh-Thao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824353/
https://www.ncbi.nlm.nih.gov/pubmed/30864105
http://dx.doi.org/10.1007/s12325-019-00912-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824353/
https://www.ncbi.nlm.nih.gov/pubmed/30864105
http://dx.doi.org/10.1007/s12325-019-00912-x

Ejemplares similares